Published in Hepatology on February 01, 2010
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol (2013) 1.46
Drug-induced cholestasis. Hepatology (2011) 1.39
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos (2013) 0.93
A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications. Oncotarget (2015) 0.86
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci (2016) 0.85
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82
An Update on Treatment of Drug-Induced Liver Injury. J Clin Transl Hepatol (2014) 0.81
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol (2015) 0.80
Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol (2014) 0.79
High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening. Nat Commun (2014) 0.79
Visualization of acute liver damage induced by cycloheximide in rats using PET with [(18)F]FEDAC, a radiotracer for translocator protein (18 kDa). PLoS One (2014) 0.79
Serotonin deficiency exacerbates acetaminophen-induced liver toxicity in mice. Sci Rep (2015) 0.79
MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol (2014) 0.77
Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison. Gastroenterol Clin Biol (2010) 0.77
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol (2011) 0.76
The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? Biomed Res Int (2015) 0.76
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs R D (2017) 0.75
Relationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immune-Mediated Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population. Pharmacogenomics J (2014) 0.75
Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. Biomed Res Int (2016) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol (2017) 0.75
Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. Medicines (Basel) (2016) 0.75
Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. Int J Mol Sci (2017) 0.75
"Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci (2017) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology (2008) 2.59
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.79
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf (2010) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology (2002) 1.02
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (2011) 0.98
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol (2009) 0.98
Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep (2012) 0.96
Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol (2003) 0.94
Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol (2013) 0.94
Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci (2003) 0.94
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol (2010) 0.93
Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep (2009) 0.93
De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant (2013) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol (2010) 0.90
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol (2012) 0.89
Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep (2011) 0.89
Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology (2012) 0.88
Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol (2005) 0.88
Factors that predict short-term intensive care unit mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol (2013) 0.85
Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl (2004) 0.85
Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time! Gastroenterology (2009) 0.85
Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol (2010) 0.85
Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol (2006) 0.85
Management of hepatitis C infection after liver transplantation. Drugs (2007) 0.85
Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One (2013) 0.84
Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements. Am J Med Sci (2011) 0.84
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet (2012) 0.84
Noninvasive markers of advanced histology in nonalcoholic fatty liver disease: are we there yet? Gastroenterology (2007) 0.84
Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. Transplantation (2016) 0.84
Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis (2011) 0.84
Acute cholecystitis after colonoscopy: a case series. Gastrointest Endosc (2011) 0.84
Irritable bowel syndrome: physicians' awareness and patients' experience. World J Gastroenterol (2012) 0.83
Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology (2007) 0.83
Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. Hepatology (2014) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Hepatic encephalopathy in patients with liver cirrhosis: is there a role of malnutrition? World J Gastroenterol (2008) 0.82